Wound complications after bevacizumab treatment in patients operated on for ovarian cancer

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4743-4747

  Koskas, Martin ^a   Chereau, Elisabeth ^a   Ballester, Marcos ^a   Selle, Frederic ^a   Rouzier, Roman ^a   Daraï, Emile ^a  

^a HÔPITAL TENON   (France)

Author keywords

Bevacizumab; Ovarian cancer; Wound complications

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FOLLOW UP; GYNECOLOGY; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VAGINA DISEASE; WOUND COMPLICATION; WOUND DEHISCENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURGICAL WOUND DEHISCENCE; SURVIVAL RATE;

EID: 78650249244     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Poole GV Jr.: Mechanical factors in abdominal wound closure: the prevention of fascial dehiscence. Surgery 97: 631-640, 1985.
2. Riou JP, Cohen JR and Johnson H Jr.: Factors influencing wound dehiscence. American journal of surgery 163: 324-330, 1992.
3. Makela JT, Kiviniemi H, Juvonen T and Laitinen S: Factors influencing wound dehiscence after midline laparotomy. American journal of surgery 170: 387-390, 1995.
4. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186, 2007.
5. Garcia AA, Hirte H, Fleming G, Yang D,Tsao-Wei DD, Roman L et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76-82, 2008.
6. Gordon MS and Cunningham D: Managing patients treated with bevacizumab combination therapy. Oncology 69(Suppl 3): 25-33, 2005.
7. Diaz JP, Tew WP, Zivanovic O, Konner J, Sabbatini PJ, Dos Santos LA et al: Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 116: 335-339, 2010.
8. Chereau E, Stefanescu D, Selle F, Rouzier R and Darai E: Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report. Am J Obstet Gynecol 200: e15-16, 2009.
9. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH et al: Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27: 3385-3390, 2009.
10. Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR et al: Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94: 650-654, 2004. (Pubitemid 39194456)
11. Chereau E, Ballester M, Selle F, Cortez A, Pomel C, Darai E et al: Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG 116: 1062-1068, 2009.
12. Abbas SM and Hill AG: Smoking is a major risk factor for wound dehiscence after midline abdominal incision; case - control study. ANZ J Surg 79: 247-250, 2009.
13. Haddad V and Macon WLt: Abdominal wound dehiscence and evisceration: contributing factors and improved mortality. American Surgeon 46: 508-513, 1980.
14. Kolb BA, Buller RE, Connor JP, DiSaia PJ and Berman ML: Effects of early postoperative chemotherapy on wound healing. Obstet Gynecol 79: 988-992, 1992.
15. Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J et al: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91: 173-180, 2005.
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
17. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697-3705, 2005.
18. August DA, Serrano D and Poplin E: 'Spontaneous', delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 97: 180-185, 2008.
19. Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B et al: A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 62: 707-709, 2009.